NasdaqGM - Nasdaq Real Time Price USD

Ocular Therapeutix, Inc. (OCUL)

7.17
+0.24
+(3.46%)
At close: May 15 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
59,647
63,723
58,443
51,494
43,522
Cost of Revenue
5,562
5,626
5,281
4,540
4,406
Gross Profit
54,085
58,097
53,162
46,954
39,116
Operating Expense
258,166
229,878
135,544
125,608
117,153
Operating Income
-204,081
-171,781
-82,382
-78,654
-78,037
Net Non Operating Interest Income Expense
7,676
6,705
-7,355
-6,224
-6,638
Other Income Expense
3,694
-28,430
9,001
13,840
78,122
Pretax Income
-192,711
-193,506
-80,736
-71,038
-6,553
Net Income Common Stockholders
-192,711
-193,506
-80,736
-71,038
-6,553
Average Dilution Earnings
--
--
-6,233
-9,245
-73,712
Diluted NI Available to Com Stockholders
-192,711
-193,506
-86,969
-80,283
-80,265
Basic EPS
-1.11
--
-1.01
-0.92
-0.09
Diluted EPS
-1.11
--
-1.02
-0.97
-0.98
Basic Average Shares
167,608.92
--
79,827.36
76,875.04
76,392.87
Diluted Average Shares
167,608.92
--
85,596.59
82,644.27
82,162.10
Total Operating Income as Reported
-204,081
-171,781
-82,382
-78,654
-78,037
Total Expenses
263,728
235,504
140,825
130,148
121,559
Net Income from Continuing & Discontinued Operation
-192,711
-193,506
-80,736
-71,038
-6,553
Normalized Income
-196,405
-165,076
-89,738
-84,879
-84,674
Interest Income
20,186
20,282
3,983
798
33
Interest Expense
12,510
13,577
11,338
7,022
6,671
Net Interest Income
7,676
6,705
-7,355
-6,224
-6,638
EBIT
-180,201
-179,929
-69,398
-64,016
118
EBITDA
-176,354
-176,143
-66,415
-61,907
2,539
Reconciled Cost of Revenue
5,562
5,626
5,281
4,540
4,406
Reconciled Depreciation
3,847
3,786
2,983
2,109
2,421
Net Income from Continuing Operation Net Minority Interest
-192,711
-193,506
-80,736
-71,038
-6,553
Total Unusual Items Excluding Goodwill
3,694
-28,430
9,002
13,841
78,121
Total Unusual Items
3,694
-28,430
9,002
13,841
78,121
Normalized EBITDA
-180,048
-147,713
-75,417
-75,748
-75,582
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/25/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EYPT EyePoint Pharmaceuticals, Inc.
5.72
+4.28%
 
VRDN Viridian Therapeutics, Inc.
12.62
+1.94%
 
INZY Inozyme Pharma, Inc.
1.4200
+5.19%
 
ETNB 89bio, Inc.
7.64
-6.83%
 
FDMT 4D Molecular Therapeutics, Inc.
3.2000
+2.24%
 
DAWN Day One Biopharmaceuticals, Inc.
6.16
-0.48%
 
CYTK Cytokinetics, Incorporated
29.84
-0.53%
 
NAMS NewAmsterdam Pharma Company N.V.
18.70
-0.27%
 
ABEO Abeona Therapeutics Inc.
5.79
+7.42%
 
MREO Mereo BioPharma Group plc
2.1800
-5.63%